Bayer AG vs Unilever PLC: Strategic Comparison

This in-depth comparison examines Bayer AG and Unilever PLC across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching Bayer AG on its own, evaluating Unilever PLC, or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between Bayer AG and Unilever PLC is widest.

On the headline numbers, Bayer AG reports annual revenue of $49.5B against $54.9B for Unilever PLC, while their respective market capitalizations stand at $38.7B and $151.9B. Bayer AG is headquartered in Germany and Unilever PLC operates from United Kingdom, and those different home markets shape how each company competes.

Bayer AG: Bayer began as a dyestuffs manufacturer in 1863 and became one of Germany's defining life-sciences companies. The same breadth that once made Bayer resilient now creates complexity: drug development, consumer brands, and agricultural technology each require different capital cycles, regulation, and risk tolerance.

Unilever PLC: Unilever used to be described by breadth: hundreds of brands, many categories, many countries. The current strategy is the opposite: fewer brands, clearer ownership, more disciplined capital allocation, and a portfolio tilted toward higher-growth personal care and beauty.

Bayer AG and Unilever PLC pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between Bayer AG and Unilever PLC.

Bayer AG business model: Bayer's business model combines regulated prescription medicines, over-the-counter consumer health brands, and agricultural inputs. Pharmaceuticals sells prescription products and earns licensing income; Consumer Health sells self-care brands through retail and pharmacy channels; Crop Science sells seeds, traits, herbicides, fungicides, insecticides, and digital agriculture solutions to growers and distributors.

Unilever PLC business model: Unilever makes money by building and distributing branded consumer products through supermarkets, drugstores, convenience channels, emerging-market distributors, e-commerce, foodservice, and direct or prestige beauty channels. Scale in procurement, manufacturing, media buying, and route-to-market supports margins.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of Bayer AG stack up against those of Unilever PLC.

Bayer AG competitive advantage: Bayer's advantage is the combination of trusted health brands, global regulatory capabilities, seed and trait assets, and customer relationships across healthcare and agriculture.

Unilever PLC competitive advantage: Unilever's advantage is a mix of trusted brands, emerging-market distribution, local manufacturing, repeat-purchase categories, Power Brand marketing scale, and deep category knowledge in personal care, home care, beauty, and foods.

Future prospects matter as much as current results. The growth strategies below explain how Bayer AG and Unilever PLC each plan to expand from here.

Bayer AG growth strategy: The growth strategy centers on Nubeqa and Kerendia in Pharmaceuticals, selective Consumer Health brand investment, crop-science portfolio discipline, lower organizational complexity, and cash generation directed toward debt reduction.

Unilever PLC growth strategy: Unilever is concentrating investment behind Power Brands, simplifying SKUs, growing beauty and wellbeing, improving execution in emerging markets, using social and digital marketing more aggressively, and reshaping the portfolio through divestitures and acquisitions.

A closer look at the financial trajectory of Bayer AG and Unilever PLC rounds out the comparison.

Bayer AG: For FY2025, Bayer reported EUR45.6B in group sales, EUR9.7B in EBITDA before special items, a EUR3.6B net loss, EUR2.1B in free cash flow, and EUR29.8B in net financial debt. Using this site's USD comparison convention, that is about $49.5B of revenue and a roughly $3.9B net loss. The figures replace older FY2024 references because the latest annual report is now the authoritative source.

Unilever PLC: Unilever's 2025 reported turnover was EUR 50.5 billion on a continuing-operations basis after Ice Cream was treated as discontinued. Underlying sales growth was 3.5%, with 1.5% volume and 2.0% price growth. This profile converts EUR 50.5 billion at an estimated 2025 average EUR/USD rate of 1.0875 for USD comparison.